Gold prices fell further on Wednesday following their worst quarter in 13 years, dropping over 16% in the three months ending June 30. The decline comes after gold hit a record high in January but fell as investors grew concerned about rising inflation and potential Federal Reserve rate hikes. Despite the drop, analysts from Amundi emphasize gold's continued importance in portfolios due to inflation volatility, high public debt, and central banks diversifying away from dollar assets. The World Gold Council also notes that many central banks plan to increase gold reserves, supporting demand in the second half of 2026.
Abeona Therapeutics announced it granted restricted stock awards to five new non-executive employees as an inducement to join the company, totaling up to 9,000 shares. These shares will vest over three years, contingent on continued employment. This ...
The global pyrometer market, valued at $544.55 million in 2025, is projected to reach $1.15 billion by 2035, growing at a CAGR of 7.57%. This growth is fueled by rising industrial automation and expansion in semiconductor manufacturing, which increas...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against BitGo Holdings, ADMA Biologics, and Erasca. The lawsuits allege these companies made false or misleading statements affe...
Step Pharma has appointed Neil J. Gallagher, MD, PhD, as a Non-Executive Director to strengthen its board as it advances dencatistat, a first-in-class CTPS1 inhibitor targeting essential thrombocythaemia, lymphoma, and solid tumours. Gallagher brings...
Ocular Therapeutix announced its participation in multiple scientific and investor conferences in July 2026, including presentations on its investigational retinal drug AXPAXLI and real-world data on anti-VEGF treatments. Key events include the OIS R...
